Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KO-2806 (Darlifarnib) in Advanced Solid Tumors
NCT06026410Phase 1Recruiting
- Sponsor
- Kura Oncology
- Start
- Oct 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of darlifarnib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 3 more (7 arms), sponsored by Kura Oncology. Primary endpoints: Rate of dose-limiting toxicities at 28 days, Descriptive statistics of adverse events at 28 days and 2 more. Started Oct 2023; status: recruiting.
02
Drugs
darlifarnib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06026410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06026410.